PFE Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 25.23% compared to Pfizer's net margin of 16.61%. Pfizer's return on equity of 4.63% beat Gilead Sciences's return on equity of 0.64%.

Pfizer has a consensus price target of $31.78, signalling upside risk potential of 18.3%. On the other hand Gilead Sciences has an analysts' consensus of $98.88 which suggests that it could grow by 10.93%. Given that Pfizer has higher upside potential than Gilead Sciences, analysts believe Pfizer is more attractive than Gilead Sciences.

Pfizer has a beta of 0.644, which suggesting that the stock is 35.588% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.12%.

Pfizer has a quarterly dividend of $0.42 per share corresponding to a yield of 6.26%. Gilead Sciences offers a yield of 3.46% to investors and pays a quarterly dividend of $0.77 per share. Pfizer pays 436.39% of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Pfizer quarterly revenues are $17.7B, which are larger than Gilead Sciences quarterly revenues of $7.5B. Pfizer's net income of $4.5B is higher than Gilead Sciences's net income of $1.3B. Notably, Pfizer's price-to-earnings ratio is 36.30x while Gilead Sciences's PE ratio is 990.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.57x versus 3.94x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 25.23% compared to Pfizer's net margin of 11.99%. Pfizer's return on equity of 4.63% beat Johnson & Johnson's return on equity of 20.88%.

Pfizer has a consensus price target of $31.78, signalling upside risk potential of 18.3%. On the other hand Johnson & Johnson has an analysts' consensus of $171.66 which suggests that it could grow by 20.66%. Given that Johnson & Johnson has higher upside potential than Pfizer, analysts believe Johnson & Johnson is more attractive than Pfizer.

Pfizer has a beta of 0.644, which suggesting that the stock is 35.588% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.514, suggesting its less volatile than the S&P 500 by 48.607%.

Pfizer has a quarterly dividend of $0.42 per share corresponding to a yield of 6.26%. Johnson & Johnson offers a yield of 3.45% to investors and pays a quarterly dividend of $1.24 per share. Pfizer pays 436.39% of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Pfizer quarterly revenues are $17.7B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Pfizer's net income of $4.5B is higher than Johnson & Johnson's net income of $2.7B. Notably, Pfizer's price-to-earnings ratio is 36.30x while Johnson & Johnson's PE ratio is 23.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.57x versus 3.94x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 25.23% compared to Pfizer's net margin of 8.48%. Pfizer's return on equity of 4.63% beat Eli Lilly and's return on equity of 66.4%.

Pfizer has a consensus price target of $31.78, signalling upside risk potential of 18.3%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25%. Given that Eli Lilly and has higher upside potential than Pfizer, analysts believe Eli Lilly and is more attractive than Pfizer.

Pfizer has a beta of 0.644, which suggesting that the stock is 35.588% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Pfizer has a quarterly dividend of $0.42 per share corresponding to a yield of 6.26%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Pfizer pays 436.39% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Pfizer quarterly revenues are $17.7B, which are larger than Eli Lilly and quarterly revenues of $11.4B. Pfizer's net income of $4.5B is higher than Eli Lilly and's net income of $970.3M. Notably, Pfizer's price-to-earnings ratio is 36.30x while Eli Lilly and's PE ratio is 85.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.57x versus 17.42x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 25.23% compared to Pfizer's net margin of 0.7%. Pfizer's return on equity of 4.63% beat Moderna's return on equity of -17.44%.

Pfizer has a consensus price target of $31.78, signalling upside risk potential of 18.3%. On the other hand Moderna has an analysts' consensus of $73.64 which suggests that it could grow by 70.59%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

Pfizer has a beta of 0.644, which suggesting that the stock is 35.588% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Pfizer has a quarterly dividend of $0.42 per share corresponding to a yield of 6.26%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 436.39% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.7B, which are larger than Moderna quarterly revenues of $1.9B. Pfizer's net income of $4.5B is higher than Moderna's net income of $13M. Notably, Pfizer's price-to-earnings ratio is 36.30x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.57x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.